Details of the Drug-Related molecule(s) Expression Atlas

General Information of Drug (ID: DMICDLV)

Drug Name
Lorlatinib Drug Info
Synonyms
Loratinib; UNII-OSP71S83EU; Lorlatinib,PF-06463922; OSP71S83EU; lorlantinib; 4clj; 4cli; Lorlatinib [USAN:INN]; Lorlatinib (JAN/USAN/INN); PF06463922(Lorlatinib); GTPL7476; SCHEMBL15261807; EX-A828; MolPort-035-789-724; KS-00000T6C; 2641AH; ZINC98208524; s7536; MFCD28144520; BDBM50018830; AKOS027250753; DB12130; CS-39
Indication
Disease Entry ICD 11 Status REF
Non-small-cell lung cancer 2C25.Y Approved [1]
Cross-matching ID
PubChem CID
71731823
ChEBI ID
CHEBI:143117
CAS Number
CAS 1454846-35-5
TTD Drug ID
DMICDLV
INTEDE Drug ID
DR0980
ACDINA Drug ID
D01222

Molecule(s) Related to This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
ALK tyrosine kinase receptor (ALK) TTPMQSO ALK_HUMAN Inhibitor [1]
Proto-oncogene c-Ros (ROS1) TTSZ6Y3 ROS1_HUMAN Inhibitor [1]

Drug-Metabolizing Enzyme (DME)
DME Name DME ID UniProt ID Highest Status REF
Cytochrome P450 3A4 (CYP3A4) DE4LYSA CP3A4_HUMAN Approved [2]
Mephenytoin 4-hydroxylase (CYP2C19) DEGTFWK CP2CJ_HUMAN Approved [2]
Cytochrome P450 3A5 (CYP3A5) DEIBDNY CP3A5_HUMAN Approved [2]
Cytochrome P450 2C8 (CYP2C8) DES5XRU CP2C8_HUMAN Approved [2]
Cytochrome P450 3A7 (CYP3A7) DERD86B CP3A7_HUMAN Approved [3]
UDP-glucuronosyltransferase 1A3 (UGT1A3) DEF2WXN UD13_HUMAN Approved [2]
UDP-glucuronosyltransferase 1A4 (UGT1A4) DELOY3P UD14_HUMAN Approved [2]

The Expression Level of Molecule(s) in Normal Tissue of Major ADME-Related Organs

Molecule Molecule Type Gene Name Liver Colon Kidney Small Intestine
Proto-oncogene c-Ros (ROS1) DTT ROS1 5.511 4.406 4.973 4.823
ALK tyrosine kinase receptor (ALK) DTT ALK 5.329 3.897 4.178 4.943
Cytochrome P450 2C8 (CYP2C8) DME CYP2C8 9.791 3.744 3.413 1.609
Cytochrome P450 3A5 (CYP3A5) DME CYP3A5 10.08 7.207 5.403 9.211
Mephenytoin 4-hydroxylase (CYP2C19) DME CYP2C19 7.867 5.142 5.52 7.08
Cytochrome P450 3A4 (CYP3A4) DME CYP3A4 11.692 6.58 4.984 9.089
Molecule Expression Atlas in Normal Tissue of Major ADME-related organs

The Expression Level of Molecule(s) between Disease Section and Healthy Individual Tissue

The Studied Disease Non-small-cell lung cancer
ICD Disease Classification 2C25.Y
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Proto-oncogene c-Ros (ROS1) DTT ROS1 1.45E-44 -1.01 -1.9
ALK tyrosine kinase receptor (ALK) DTT ALK 7.19E-15 0.18 0.61
Cytochrome P450 2C8 (CYP2C8) DME CYP2C8 5.28E-05 1.90E-02 1.09E-01
Cytochrome P450 3A5 (CYP3A5) DME CYP3A5 3.12E-38 -1.81E+00 -2.01E+00
Mephenytoin 4-hydroxylase (CYP2C19) DME CYP2C19 1.08E-02 2.60E-02 1.59E-01
Cytochrome P450 3A4 (CYP3A4) DME CYP3A4 5.59E-39 -3.76E-01 -1.64E+00
Molecular Expression Atlas between Disease Section and Healthy Individual Tissue

References

1 2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89.
2 FDA label of Lorlatinib. The 2020 official website of the U.S. Food and Drug Administration.
3 Product characteristics of Lorviqua.